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The objective of the current study was to develop a validated stability-indicating assay method (SIAM) for risperidone
after subjecting it to forced decomposition under hydrolysis, oxidation, photolysis, and thermal stress conditions. The liquid
chromatographic separation was achieved isocratically on a symmetry C18 column (5µm size, 250mm × 4.6mm i.d.) using a
mobile phase containing methanol: acetonitrile (80:20, v/v) at a ﬂow rate of 1mL/min and UV detection at 280nm. Retention
time of risperidone was found to be 3.35 ±0.01. The method was linear over the concentration range of 10–60µg/mL(r2 = 0.998)
with a limit of detection and quantitation of 1.79 and 5.44µg/mL, respectively. The method has the requisite accuracy, speciﬁcity,
sensitivity,andprecisiontoassayrisperidoneinbulkformandpharmaceuticaldosageforms.Degradationproductsresultingfrom
the stress studies did not interfere with the detection of Risperidone, and the assay is thus stability indicating.
1.Introduction
Risperidone,4-[2-[4-(6-ﬂuorobenzo[d]isoxazol-3-yl)-1-pip-
eridyl]ethyl]-3-methyl-2,6-diazabicyclo[4.4.0]deca-1,3-dien-
5-one an atypical antipsychotic drug used for the treatment
of schizophrenia, the mixed and manic states associated
with bipolar disorder, and irritability in children with
autism [1]. Blockade of dopaminergic D2 receptors in the
limbic system alleviates positive symptoms of schizophrenia
such as hallucinations, delusions, and erratic behavior and
speech. Blockade of serotonergic 5-HT2 receptors in the
mesocortical tract causes an excess of dopamine, resulting
in an increase in dopamine transmission and an elimination
of core negative symptoms. It has high aﬃnity for D2
dopaminergic receptors. It has actions at several 5-HT
(serotonin) receptor subtypes. These are 5-HT2C, linked to
weight gain, 5-HT2A, linked to its antipsychotic action and
relief of some of the extrapyramidal side eﬀects experienced
with the typical neuroleptics through action at 5-HT1A.L i k e
other 5-HT2 antagonists, risperidone also binds at alpha (1)-
adrenergic receptors and, to a lesser extent, at histamine
H1 and alpha (2)-adrenergic receptors [2]. Several analytical
methods have been reported in the literature for the analysis
of Risperidone from pharmaceutical dosage form. The
techniques include chemiluminescence [3], RP HPLC [4],
TLC [5], and visible spectrophotometry [6] and so forth
forms.TherearenumerousmethodstoquantifyRisperidone
in biological ﬂuid and human plasma, including HPLC
combined with capillary electrophoresis [7], HPLC-DAD
[8],HPLC-MS/MS[9],RP-HPLC[10],LC-MS/MS[11–13],
aﬃnity capillary electrophoresis, and H1 NMR spectroscopy
[14]. These methods [11–14] are complicated, costly and
time consuming in comparison to a simple HPLC-UV
method. Currently, most of the separations are performed by
HPLC for reasons of robustness and familiarity of analysts
with this technique. About speciﬁcity for HPLC method,
peak purity tests may be useful to show that the analyte
chromatographic peak is not attributable to more than
one component. The previous published methods are not
directly applicable for this issue and need more investigation2 International Journal of Analytical Chemistry
for method development and validation. So, an approach
was made to develop a simple, precise, accurate, speciﬁc,
and robust stability- indicating HPLC-UV method for the
quantitativedeterminationofRisperidoneinpharmaceutical
dosage forms and applied to the assay of Risperidone in
tablets and bulk form.
2. Experimental
2.1. Chemicals and Reagents. Risperidone working standard
powder with 99.98% purity was kindly gifted by Tripada
Pharmaceuticals, Ahmedabad, India and was used without
further puriﬁcation. RISPERDAL tablets containing 2mg
Risperidone as per labelled claim were obtained from
local market. methanol, acetonitrile, and water were of
HPLC grade, and sodium hydroxide, and hydrochloric acid,
hydrogen peroxide were of analytical grade obtained from E.
Merck (India) Ltd., Mumbai. All chemicals were at least of
analytical grade and used as received.
2.2. HPLC Instrumentation and Conditions. The present
work was carried out on isocratic high pressure liquid
chromatography and consisted of pump (Cyberlab TM,
USA) with universal loop injector (Rheodyne) of injec-
tion capacity 20µL. Detector consists of photodiode array
detector; the reversed phase column used was RP-C18
(5µm size, 250mm × 4.6mm i.d.) at ambient temperature.
Separation was achieved using a mobile phase consist-
ing of methanol:acetonitrile (80:20, v/v) at a ﬂow rate
of 1mL/min. The eluted compounds were monitored at
280nm. The column was maintained at ambient tempera-
ture, and an injection volume of 20µL was used. The mobile
phase was ﬁltered through 0.45 micron membrane ﬁlter and
ultrasonicated for 10 minutes prior to use. For analysis of
forced degradation samples, the photodiode array detector
was used in scan mode with a scan range of 200–400nm.
Peak homogeneity was expressed in terms of peak purity
valuesandwasobtaineddirectlyfromspectralanalysisreport
obtained using the instrument software.
2.3. Preparation of Stock and Standard Solutions. A1m g / m L
stock solution of Risperidone was prepared in HPLC grade
acetonitrile.Substocksolutionwaspreparedfromstocksolu-
tion by diluting 10mL standard stock solution up to 100mL
to get 100µg/mL. Aliquots of the standard Substock solution
of Risperidone were transferred into 10mL volumetric ﬂasks
and the solutions were made up to volume with mobile
phase to give ﬁnal concentrations of 10, 20, 30, 40, 50,
and 60µg/mL. Each 20µL standard solution was injected
into the column after ﬁltration using 0.2 micron membrane
ﬁlter.
2.4. Preparation of Tablets for Assay. Twenty tablets were
weighed, crushed, and mixed in a mortar and pestle. A
portion of powder equivalent to the weight of one tablet was
accurately weighed and transferred into 10mL volumetric
ﬂask and made up to the volume with mobile phase
and mixed well. Six of such solutions were prepared. The
volumetric ﬂasks were sonicated for 20 minutes to aﬀect
complete dissolution of the Risperidone, and the solutions
werethenmadeuptothevolumewithmobilephase.Suitable
aliquots of solution were ﬁltered through a 0.45 micron
nylon ﬁlter. 2mL of the ﬁltered solution was transferred to
a 10mL volumetric ﬂask and made up to the volume with
mobilephasetoyieldconcentrationofRisperidone40µg/mL
in the range of linearity previously described.
2.5. Forced Degradation Studies of API. In order to deter-
mine the stability indication of the analytical method and
assay, Risperidone tablets and Risperidone API powder
were stressed under various conditions to conduct forced
degradation studies [15]. Regulatory guidance in ICH Q2A,
Q2B, Q3B, and FDA 21 CFR section 211 requires the
development and validation of stability-indicating potency
assays. Unfortunately, the current guidance documents do
not indicate detailed degradation conditions in stress testing.
However, the forced degradation conditions, stress agent
concentration, and time of stress were selected based on
trial and error method, so that the degradation of drug
preferably remains between 10% and complete degradation.
As Risperidone is practically insoluble in water and is readily
soluble in methanol, methanol was used as cosolvent in
all studies. All solutions of Risperidone used in forced
degradation studies were prepared with ﬁnal concentrations
of 20µg/mL.
2.5.1. Acid Degradation Studies. 100mg of Risperidone sam-
ple was taken into a 100mL round bottom ﬂask, 10mL of
0.1M hydrochloric acid solution was added, and contents
were mixed well and kept for constant stirring for 12hr
at room temperature. 2mL of this solution was taken in
100mL volumetric ﬂask and neutralized with 0.2mL of
0.1M sodium hydroxide and then diluted to 100mL with
diluent.
2.5.2. Alkali Degradation Studies. 100mg of Risperidone
sample was taken into a 100mL round bottom ﬂask, 10mL
of 0.1M sodium hydroxide solution was added, and contents
were mixed well and kept for constant stirring for 36hr
at room temperature. 2mL of this solution was taken in
100mL volumetric ﬂask and neutralized with 0.2mL of
0.1M hydrochloric acid and then diluted to 100mL with
diluent.
2.5.3. Oxidation. 100mg of Risperidone sample was taken in
100mL round bottom ﬂask, 10mL of 3% hydrogen peroxide
solution was added, and contents were mixed well at room
temperature. After 4hr, 2mL of this solution was diluted to
100mL with diluent.
2.5.4. Temperature Stress Studies. 1g of Risperidone sample
was taken into a petridish and kept in oven at 80◦C for 24hr.
10mg of this sample was taken into a 100mL volumetric
ﬂask,dissolvedindiluentanddilutedtovolumewithdiluent.
2mLofthissolutionwastakenin10mLvolumetricﬂaskand
then diluted to 10mL with diluent.International Journal of Analytical Chemistry 3
Table 1: Precision study.
Drug Concentration (µg/mL) Intraday precision Calculated
concentration±S.D. (µgmL−1), R.S.D.
Interday precision calculated
concentration±S.D. (µgmL−1), R.S.D.
Risperidone
20 19.88 ±0.20, 1.04 20.04 ±0.24, 1.22
30 29.85 ±0.26, 0.89 29.82 ±0.26, 0.88
40 39.92 ±0.21, 0.52 39.87 ±0.27, 0.68
Table 2: Recovery study.
Label claim Mg/tablet Amount added % Total amount added (mg) Amount recovered∗ (mg)±SD % Recovery±SD (n = 3)
Risperidone 50 1 0.99 ±0.02 99.66 ±1.79
2 100 2 2.01 ±0.02 100.21 ±1.11
150 3 3.01 ±0.04 100.31 ±1.46
∗Mean ±%SD for three determinations.
2.5.5. Photostability. 1g of Risperidone sample was taken in
toapetridishandkeptinphotostabilitychamber200Wh/m2
in UV light and 1.2 million l × h in visible light for 36hr.
10mg of this sample was taken in to a 100mL volumetric
ﬂask, dissolved in diluents, and diluted to volume with
diluent. 2mL of this solution was taken in 10mL volumetric
ﬂask and then diluted to 10mL with diluent.
3. Results andDiscussion
3.1. HPLC Method Development and Optimization. AR P -
C18 column (250mm × 4.6mm i.d., 5µmp a r t i c l es i z e )
maintained at ambient temperature (25◦C) was used for the
separation and the method validated for the determination
of Risperidone in pharmaceutical dosage forms. Initially
mobile phase composed of n-hexane:ethanol:methanol
(50:35:15, v/v/v) was tried, but analyte could not be
resolved in 20min run time. Then diﬀerent mobile phase
composition like 0.1% formic acid:acetonitrile (40:60, v/v);
sodium dihydrogen phosphate buﬀer-acetonitrile (55:45,
v/v) adjusted to pH 6.0 at 1.5mL/min ﬂow rate were
tried, but poor resolution was obtained. So the addition
of acetonitrile in above mobile phase and mobile phase
composedofmethanol:acetonitrile:0.05Mpotassiumdihy-
drogen phosphate pH 7 (65:25:10 v/v) at 1.5mL/min ﬂow
rate were tried but satisfactory peak was not observed. Then
buﬀer solution was replaced with organic solvent to simplify
the tediousness of preparation of the mobile phase. The
mobile phase methanol:acetonitrile (60:40, v/v) was tried
and get resolved peak of analyte and degradants. Improve-
ment of peak shape and symmetry was done by changing
diﬀerent ratio and ﬂow rate of methanol:acetonitrile:water.
A satisfactory separation and peak symmetry for the drug
and its degradation products were obtained with mobile
phase consisting of methanol:acetonitrile (80:20,v/v) at
1mL/min ﬂow rate and ambient temperature.
3.2. Validation. The method was validated with respect to
parameters including linearity, limit of quantitation (LOQ),
limit of detection (LOD), precision, accuracy, speciﬁcity,
robustness, solution stability, and system suitability.
3.2.1. Linearity. The calibration curves constructed for
Risperidone were linear over the concentration range of 10–
60µg/mL. Peak areas of Risperidone were plotted versus
Risperidone concentration and linear regression analysis
performed on the resultant curve. Typically, the regression
equation for the calibration curve was found to be y =
5203x +8933 with 0.999 correlation coeﬃcient.
3.2.2. LOQ and LOD. The LOQ and LOD were determined
based on signal-to-noise ratios, using an analytical response
of 10 and three times of the background noise, respectively
[16]. The LOQ and LOD were found to be 5.44µg/mL and
1.79µg/mL, respectively.
3.2.3. Precision. Table 1 provides data obtained from the
precision experiments. The R.S.D. values for intraday and
interday precision were <1.04% and <1.22%, respectively,
thereby indicating that the method was suﬃciently precise.
A similar qualitative separation of the drug was obtained
even on analysis on a diﬀerent chromatographic system on
ad i ﬀerent day, indicating that the method has suﬃcient
intermediate precision.
3.2.4. Accuracy. Percentage recovery was calculated from
diﬀerences between the peak areas obtained for fortiﬁed and
unfortiﬁed solutions. As shown from the data in Table 2,
excellent recoveries were made at each added concentration
of drug.
3.2.5. Speciﬁcity. Speciﬁcity is the ability of the method
to measure the analyte response in the presence of its
degradation products. The method was found to be speciﬁc
to the drug. Speciﬁcity was established by determination of
purity of the drug peak using a PDA detector. Also, the
resolution factor of the drug peak was determined with
respect to the nearest resolving peaks.
3.2.6. Robustness. The robustness was illustrated by get-
ting the retention time, when mobile phase ﬂow rate
(±0.2mL/min), organic solvent ratio (±5%), and column
temperature (±2◦C) were deliberately varied.4 International Journal of Analytical Chemistry
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Figure 1: Typical HPLC chromatograms of: (a) acid hydrolysis-degraded active pharmaceutical ingredient (API), (b) base hydrolysis-
degraded API, (c) oxidative degraded API, (d) thermal degrade API, and (e) photodegraded (API).
3.2.7.SolutionStability. ThesolutionstabilityofRisperidone
in diluents was determined by leaving 0.1mg/mL sample
solution in a tightly capped volumetric ﬂask at room
temperature for 48hr and measuring the amount for every
6hr. The solution stability of Risperidone assay (in diluent)
was determined by leaving 0.1mg/mL Risperidone solution
in tightly capped volumetric ﬂasks at room temperature
for 48hr during which they were assayed at 6hr intervals
and compared the results with those obtained from freshly
prepared solution. The mobile phase was prepared at the
beginning of the study period and not changed during
the experiment. The %RSD values for solution stabilityInternational Journal of Analytical Chemistry 5
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Figure 2: Resultant HPLC chromatograms following the analysis of a standard solution of Risperidone 20µg/mL (a) and Risperidone tablets
(2mg) (b).
Table 3: System suitability parameters.
System suitability parameters Risperidone
Retention times (RT) 3.34
Theoretical plates (N) 3232.65
Tailing factor (AS) 1.83
experiments were calculated and found to be 1.36% and
1.45% for purity and assay methods, respectively. All the
samples were found to be stable up to 48hr.
3.2.8. System Suitability. The system suitability test was
applied to a representative chromatogram to check the
v a r i o u sp a r a m e t e r ss u c ha sc o l u m ne ﬃciency, resolution,
precision, and peak tailing. The result obtained is shown
in Table 3. All these parameters were evaluated with the
backgroundofregulatoryrequirements,whichsuggestsgood
chromatographic condition.
3.3. Stability Studies. All stressed samples in both solid
and solution state remained colorless. HPLC studies
on Risperidone under diﬀerent stress conditions using
methanol:acetonitrile (80:20, v/v) as the solvent system
suggested the following degradation behavior as shown in
Figure 1. Summary of degradation was shown in Table 4.
3.3.1. Acidic Condition. The drug gradually decreased with
time on reﬂuxing with 0.1M HCl at 12hr at room tempera-
ture, forming degradation products at RRT 4.20. At the end
of 24h, around 26.89% fall in drug peak area was observed,
and fronting was observed in analyte peak.
3.3.2. Degradation in Alkali. The drug was found to compar-
atively stable to alkaline hydrolysis. On reﬂuxing the drug in
0.1M NaOH for 36hrs, around 17.53% of the drug was only
degraded. Degradants product was appeared at RRT 2.62.
3.3.3. Oxidative Conditions. The drug was highly labile to
hydrogen peroxide (3%) at room temperature. After 4hr,
steep fall in the drug peak area was observed. Major
degradants products were appeared at RRT 2.67, and risperi-
done was degraded up to 68.54%. At the end of 6 hr, almost
complete degradation of the drug was observed with the
corresponding rise in the major degradation peak.
3.3.4. Thermal Degradation. The solid-state studies showed
that Risperidone was comparatively stable to the eﬀect of
temperature. When the drug powder was exposed to dry
heatat80◦Cfor24hr30.09%degradationwasobservedwith
corresponding rise to degradants products at RRT 2.75.
3.3.5. Photolytic Conditions. No major degradation product
was observed after exposure of solid drug kept in UV light.
Minor degradants products at RRT 2.76 with 26.62% fall in
Risperidone after 36hr.
3.3.6. Assay. The proposed method was applied to the
determination of Risperidone in risperdal. A typical chro-
matogram obtained following the assay of Risperidone
tablets is depicted in Figure 2. The result of these assays
yielded 99.88% (%R.S.D. = 1.31%) of labelled claim for the
tablets.
4. Conclusions
A validated stability-indicating HPLC analytical method
has been developed for the determination of Risperidone
in API. The results of stress testing undertaken according
to the International Conference on Harmonization (ICH)
guidelines reveal that the method is selective and stability
indicating.Theproposedmethodissimple,accurate,precise,
speciﬁc, and has the ability to separate the drug from
degradation products and excipients found in the tablet
dosage forms. The method is suitable for the routine6 International Journal of Analytical Chemistry
Table 4: Summary of forced degradation results.
Sr. no. Stress/exposure condition Drug remained/20µg/mL±SD
(n = 3) Retention time of degradants % Recovery % Degradation
(1) Acid degradation 14.62 ±0.16 4.20 73.10 26.89
(2) Base degradation 16.49 ±0.16 2.62 82.46 17.53
(3) Oxidation 6.29 ±0.08 2.67 31.45 68.54
(4) Thermal degradation 13.98 ±0.11 2.75 69.90 30.09
(5) Photo degradation 14.67 ±0.12 2.76 73.37 26.62
analysis of Risperidone in either bulk API powder or in
pharmaceutical dosage forms. The simplicity of the method
allows its application in laboratories that lack sophisticated
analytical instruments such as LC–MS or GC–MS. These
methods are complicated and costly rather than a simple
HPLC-UV method.
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